Montelukast Treatment to Reduce Inflammation and Heart Damage in Adults With Acute Myocardial Infarction A Randomized Controlled Phase 2 Trial

What this Trial Is About

Researchers are evaluating the effects of Montelukast in patients who have experienced Acute Myocardial Infarction AMI, commonly known as a heart attack. This randomized controlled clinical trial aims to study whether Montelukast can influence inflammatory markers and reduce heart damage after an AMI. The trial is conducted by the Faculty of Pharmacy and Faculty of Medicine at Mansoura University to provide high-quality evidence regarding Montelukasts potential heart-protective and anti-inflammatory effects. Participants will be randomly assigned to one of two groups one group will receive Montelukast 10 mg oral tablets, while the other will receive a placebo. This triple-blinded study ensures unbiased assessment of the medications impact. The treatment period and dosing schedules are designed to closely monitor changes in inflammation and heart injury markers. During the study, participants will have blood tests to measure inflammatory biomarkers such as IL-6, TNF-, hs-CRP, Galectin-3, and LTB4 at the start, on day 3, and at week 4. Researchers will track how these markers change over time to assess the drugs effects. The study will also monitor safety and other health indicators, with participant involvement lasting several weeks to cover the initial and follow-up periods.

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction